TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Response of TB to DOTS therapy in people living with HIV/AIDS: A prospective clinical study

B. Bhargav Prasad, V.A. Narasimha Raju, P. Jayakar Babu
Feb. 20, 2012, 10:50 p.m.

Abstract

Background: In the patients with HIV and concomitant tuberculosis (TB), the response to directly observed therapyshort course (DOTS) is variable because of immunosupression, opportunistic infections and intolerance due to drugs including anti-retroviral treatment (ART).

Aim: To study the response of TB to DOTS in immunosupressed patients with HIV.
Material and Methods: Patients who attended our department during 2009-2010 with respiratory symptoms were screened. Study group comprised patients diagnosed with HIV with TB. Study group was further divided in A-CD4 count <150/ cmm, receiving DOTS with ART and B- CD4 count >150/cmm, receiving DOTS alone. Control group comprised patients with TB alone, on DOTS.

Results: Three hundred and forty three patients were diagnosed with TB of which 37, diagnosed with HIV with TB, were included in study (7 with CD4 count <150/cmm, receiving DOTS with ART and 30 with CD4 count >150/cmm, receiving DOTS alone). Control group comprised of 306 patients with TB alone, on DOTS. In the study group, of 7 patients in subgroup A, 2 patients died and 5 patients defaulted. All 30 patients in subgroup B were improved. Improvement was observed in all patients in control group.

Conclusions:Concomitant use of DOTS and ART increase in the incidence of therapy default to DOTS otherwise six months of therapy is enough to cure TB in HIV cases.

Read the full study here.